相关实验视频

Updated: Jun 6, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

新型生物标志物作为降低补偿性高级慢性心力衰竭的潜在预测者 - - 单中心研究

Tobias Fröhling¹, Dilvin Semo¹, Moritz Mirna²

¹Department for Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, 48149 Münster, Germany.

Journal of clinical medicine

|November 27, 2024

概括

新型生物标志物可溶性尿酶类型等离子体激活受体 (suPAR),生长/分化因子15 (GDF-15),血管细胞粘附分子1 (VCAM-1) 和心型脂肪酸结合蛋白 (H-FABP) 在检测急性不补偿性心力衰竭方面表现有前途. 这些标记可能有助于区分补偿和失补偿心力衰竭患者.

科学领域:

心脏病学心脏病学
生物标志物发现发现
内部医学内部医学

背景情况:

心力衰竭 (HF) 带来了重大的诊断和治疗挑战.
目前用于HF脱补偿的生物标志物缺乏特异性,在其他条件下经常升高.
区分急性失补偿性HF和补偿性HF需要改进的诊断工具.

研究的目的:

评估四种新型心血管生物标志物的预测潜力:suPAR,H-FABP,VCAM-1和GDF-15.
评估这些生物标志物,以检测HF患者的心脏衰减的情况.
要区分急性失补偿性HF和补偿性HF.

主要方法:

预计将招募146名心力衰竭患者.
血清生物标记度使用酶相关免疫吸收试验 (ELISA) 进行分析.
生物标志物水平与临床和生物化学参数的相关性;对心脏失补偿的预测价值的评估.

主要成果:

在急性不补偿性HF和补偿性HF中观察到的suPAR,H-FABP,VCAM-1和GDF-15的显著升高水平.
suPAR (1.6倍),H-FABP (2.2倍),VCAM-1 (1.6倍) 和GDF-15 (1.7倍) 显示显著增加 (p < 0.0001 至 p = 0.0458).这些都显示出明显的增长.
单变量逻辑回归证实了生物标志物度与心脏衰竭风险之间的显著关联.

结论:

新型生物标志物suPAR,GDF-15,VCAM-1和H-FABP显示出有助于HF治疗决策的潜力.
这些生物标志物可能有助于识别疑似心脏衰退的患者.
需要进一步的研究,以建立可靠,敏感和特定的早期检测工具,考虑到功能等因素.

关键词:

在HFmrEFEF中使用.这就是HFrEFEF.急性不补偿性心力衰竭是什么生物标志物生物标志物心脏衰竭是因为心脏衰竭.

更多相关视频

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

相关概念视频

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...